There are currently 148 active clinical trials seeking participants for Melanoma research studies. The states with the highest number of trials for Melanoma participants are California, Texas, Florida and Pennsylvania.
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
NCT04083599
Recruiting
To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Alaska Oncology and Hematology LLC, Anchorage, Alaska +75 locations
Conditions: Malignant Solid Tumor, Melanoma, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Register for Updates
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
NCT06448364
Recruiting
The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose. This study is seeking participants who have solid tumors that: have advanced (cancer that doesn't disappear or stay away with treatment) or has spread to other parts of the body (metastatic). This includes (but limited to) the following cancer types: Non-Small Cell Lung Can... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: NEXT Oncology, San Antonio, Texas +3 locations
Conditions: Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Register for Updates
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247
Recruiting
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: The Angeles Clinic and Research Institute - California, Los Angeles, California +11 locations
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Register for Updates
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
NCT05538130
Recruiting
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times p... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/31/2024
Locations: Highlands Oncology Group, PA, Fayetteville, Arkansas +28 locations
Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
Register for Updates
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
NCT06438588
Recruiting
This clinical trial assesses an effective and translatable care model to understand and reduce the adverse effects that cancer patients experience during their treatment therapies and thereby enhance their well-being and quality of life. Excessive immune activation can affect multiple organs with the most common adverse effects being skin rash, diarrhea, colitis, fatigue, hypothyroidism and anorexia. A restrictive calorie diet, mostly of fat and complex carbohydrates, will mimic fasting and incr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT03897881
Recruiting
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: University of Arizona, Tucson, Arizona +20 locations
Conditions: Melanoma
Register for Updates
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
NCT05607095
Recruiting
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Memorial Sloan Kettering Westchester, Harrison, New York +1 locations
Conditions: Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
Register for Updates
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
NCT06285097
Recruiting
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study will further evaluate PF-07820435 at the recommended dose for combination expansion in patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota, Florida +11 locations
Conditions: Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: City of Hope, Duarte, California +9 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Register for Updates
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369
Recruiting
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Florida Cancer Specialists, Lake Mary, Florida +2 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Register for Updates
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
NCT04971499
Recruiting
This phase 1/2 trial will be conducted in two parts. Part 1 (Dose Selection) is designed to find the dose of dapansutrile with acceptable tolerability in combination with pembrolizumab. Part 1 will consist of up to 2 dose selection cohorts to evaluate the safety and tolerability of dapansutrile + pembrolizumab in patients with PD-1 resistant melanoma to find the recommended part 2 dose (RP2D). Part 1 will include a lead-in phase of dapansutrile monotherapy at 500 mg PO BID. At day 15, combinatio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Melanoma
Register for Updates
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT05912244
Recruiting
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut +8 locations
Conditions: Melanoma
Register for Updates